The EML4-ALK fusion gene was present at a high frequency in Chinese NSCLC patients, particularly in those with adenocarcinomas lacking EGFR/KRAS mutations.     ///    "Within this cohort, the EML4-ALK fusion gene was identified in 12 tumors (11.6%). "    ///    "Further analysis revealed that EML4-ALK was present at a frequency of 16.13% (10/62) in patients with adenocarcinomas, 19.23% (10/52) in never-smokers, and 42.80% (9/21) in patients with adenocarcinomas lacking EGFR and KRAS mutations. "    ///    "The EML4-ALK fusion was associated with non-smokers (P = 0.03), younger age of onset (P = 0.03), and adenocarcinomas without EGFR/KRAS mutations (P = 0.04). "    ///    Concurrent deletion in EGFR exon 19 and fusion of EML4-ALK was identified for the first time in a Chinese female patient with an adenocarcinoma.     ///    "A trend towards improved survival was observed for patients with the EML4-ALK fusion, although it was not statistically significant (P = 0.20). "    ///    The EML4-ALK fusion appears to be tightly associated with ALK mRNA expression levels.     ///    "A trend towards improved survival was observed for patients with the EML4-ALK fusion, although it was not statistically significant (P = 0.20)."